• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 20, 2014

View Archived Issues

Pharma: clinic roundup

Novo Nordisk A/S, of Bagsvaerd, Denmark, reported positive results from pathfinder2, the first phase III trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for hemophilia A patients. Read More

Pharma: other news to note

Ferring Pharmaceuticals Inc., of Parsippany, N.J., reported FDA approval of new labeling for their fertility products, Menopur and Bravelle. Read More

Clinic roundup

Cellceutix Corp., of Beverly, Mass., said the seventh cohort is under way in the phase I trial of anticancer drug candidate, Kevetrin, dosing 165 mg/m2 of Kevetrin compared to 110 mg/m2 in the prior cohort. Read More

Other news to note

Bioalliance Pharma SA, of Paris, said it executed a license agreement with Innocutis Holding LLC, of Charleston, S.C., to commercialize Sitavig (acyclovir Lauriad) for the treatment of recurrent labial herpes in North America. Under the terms, Bioalliance is eligible to receive a total of $5 million up front and milestone payments. Read More

Stock Movers

Read More

Financings roundup

C3 Jian Inc., of Los Angeles, said it closed a series D financing for total proceeds of $60.5 million that will be used to support continued clinical development of their lead product, C16G2, a proprietary peptide-based antimicrobial drug specifically targeting Streptococcus mutans. Read More

Through thick and thin: Portola starts phase III with Factor Xa reverser

Still enrolling a pivotal trial of its own Factor Xa inhibitor betrixaban, Portola Pharmaceuticals Inc. launched a new phase III study, this one testing andexanet alfa, designed to reverse the action of the anticoagulant class. Read More

‘Vulcanizing’ generic labeling is fundamental policy change for FDA

Whether the needs of the many outweigh the needs of the few is the debate swirling around the FDA’s proposed rule that would allow generic drugmakers to change their labeling independent of the brand drug. Read More

Medigene licenses Rhudex in PBC to Dr. Falk Pharma

Shares in Medigene AG edged up 8 percent Thursday on news of a licensing deal for its small-molecule CD80 (B7-1) inhibitor Rhudex with Dr. Falk Pharma GmbH. Read More

‘Alder’ or nothing: biopharma files for $115M IPO

The bulls marched on as Alder Biopharmaceuticals Inc. joined the growing queue of biotechs seeking to prevail on the public markets. The Bothell, Wash.-based company filed a registration statement with the SEC seeking to raise up to $115 million in its initial public offering (IPO) to fund its ongoing clinical program for lead compound ALD403, a monoclonal antibody targeting calcitonin gene-related peptide, or CGRP, to prevent migraine headache. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe